ALK Abello Secures UK Approval for Needle-Free Adrenaline Treatment for Young Children — ALK-Abelló A/S

Event summary

ALK Abello's EURneffy 1 mg received UK marketing authorization on June 15, 2026, as the first needle-free adrenaline treatment for children aged 4+ weighing 15–30 kg at risk of anaphylaxis.
The approval extends ALK's existing EURneffy 2 mg product, previously approved for adults and children weighing ≥30 kg.
EURneffy 1 mg demonstrated comparable absorption and pharmacodynamic effects in children as the 2 mg dose in larger individuals.
The product has a 24-month shelf life and requires no special storage, with a total of 30 months for the 2 mg version.

The big picture

This approval addresses a critical gap in anaphylaxis treatment for younger children, who have historically relied on injectable adrenaline despite barriers like needle phobia and administration errors. ALK Abello's needle-free solution could set a new standard in emergency allergy care, potentially reshaping the competitive landscape. The company's global expansion strategy, with approvals already in multiple regions, positions it as a key player in the allergy treatment market.

What we're watching

Market Penetration: How ALK Abello will leverage this approval to expand its market share in the UK and Europe, particularly among pediatric patients.
Competitive Dynamics: Whether the needle-free format will drive preference over traditional adrenaline auto-injectors, affecting competitors like ARS Pharmaceuticals.
Regulatory Expansion: The pace at which ALK can secure similar approvals in other major markets, given the existing approvals in the US, Japan, China, Australia, and Canada.